Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURQUOISE-III in genotype 1b chronic hepatitis C with compensated cirrhosis
2014-001953-18Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ombitasvir, paritaprevir, ritonavir and dasabuvir in chronic hepatitis C (CHC) and Cirrhosis, sponsored by AbbVie Inc. Primary endpoint: SVR12 rate. Started Aug 2014; status: completed.
02
Drugs
ombitasvirparitaprevirritonavirdasabuvir
03
Conditions
chronic hepatitis C (CHC)Cirrhosis
Beyond the preview
Go deeper on 2014-001953-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001953-18.